Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Trastuzumab Deruxtecan Approved in Japan for HER2-Mutated Metastatic NSCLC

August 23rd 2023

Japan’s Ministry of Health, Labour, and Welfare has approved fam-trastuzumab deruxtecan-nxki for use in adult patients with unresectable advanced or recurrent, HER2-mutant non–small cell lung cancer that has progressed following chemotherapy.

Tiragolumab Plus Atezolizumab Falls Short in Unexpected OS Analysis in PD-L1–High NSCLC

August 23rd 2023

The addition of the investigational anti-TIGIT immunotherapy tiragolumab to atezolizumab demonstrated a numerical but not statistically significant improvement in overall survival vs atezolizumab alone as frontline therapy for patients with PD-L1–high, locally advanced or metastatic non–small cell lung cancer.

Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC

August 22nd 2023

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

NSCLC: Biomarker Testing Strategies and Turnaround Time

August 22nd 2023

Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.

Adjuvant Furmonertinib Shows Efficacy, Tolerability in EGFR+ NSCLC With High-Risk Factors

August 20th 2023

Furmonertinib had efficacy and an acceptable toxicity profile when utilized as adjuvant treatment in EGFR-mutated, stage IA2-IIIA non–small cell lung cancer with high-risk pathological factors who have undergone radical surgery

Megahed on the Effects of NGS on First-Line Treatment Decisions in NSCLC

August 17th 2023

Ahmed Megahed, MBBCh, discusses the rationale for investigating the effects of next-generation sequencing on first-line treatment decisions for patients with stage IV non–small cell lung cancer.

Dr Santos on the ADAURA Trial of Adjuvant Osimertinib in EGFR-Mutant NSCLC

August 17th 2023

Edgardo S. Santos, MD, FACP, discusses key survival data from the pivotal phase 3 ADAURA trial in early-stage non–small cell lung cancer.

Dr Massarelli on Addressing Unmet Needs in SCLC

August 16th 2023

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in the treatment of patients with small cell lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as how further research may help mitigate these needs.

NK T-Cell Agonist Under Investigation in Combination With Pembrolizumab in Melanoma and NSCLC

August 16th 2023

The natural killer T-cell agonist IMM60 may overcome resistance to PD-1 inhibitors when combined with immunotherapy in patients with melanoma and non–small cell lung cancer.

Repotrectinib Sustains ORR, Safety in Locally Advanced or Metastatic ROS1+ NSCLC

August 16th 2023

Treatment with repotrectinib continued to produce high and durable responses with a manageable safety profile in patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer who were naïve to a TKI or previously treated with 1 TKI and no chemotherapy.

Dr Spira on the Ongoing Investigation of MYTX-011 in NSCLC

August 15th 2023

Alexander I. Spira, MD, PhD, FACP, discusses a phase 1 study of the antibody-drug conjugate MYTX-011 in patients with non–small cell lung cancer.

Liquid vs Tissue Biopsies in NSCLC

August 15th 2023

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

Biomarker Testing in Non-Small Cell Lung Cancer

August 15th 2023

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

Dr Qin on Choosing Between Targetable Agents in EGFR Exon 20–Mutated Lung Cancer

August 14th 2023

Angel Qin, MD, discusses her process when choosing between targetable agents for patients with EGFR exon 20–mutated lung cancer.

FDA Grants Orphan Drug Designation to Quratusugene Ozeplasmid for Small Cell Lung Cancer

August 14th 2023

The FDA has granted an orphan drug designation to quratusugene ozeplasmid (Reqorsa) for the treatment of patients with small cell lung cancer.

BAT8006 Elicits Disease Control, Safety in Advanced Ovarian Cancer and Other Solid Tumors

August 14th 2023

Treatment with the folate receptor–α antibody-drug conjugate BAT8006 led to responses with a manageable safety profile in patients with advanced solid tumors, including ovarian cancer, breast cancer, and cervical cancer.

Novel and Emerging Frontline Treatment Strategies in SCLC

August 14th 2023

Before closing out their first module, expert oncologists consider novel treatment strategies and agents in the frontline setting of stage small cell lung cancer.

Novel Treatment Approaches for SCLC and Future Perspectives

August 14th 2023

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.

Real-World Data and Observed AEs With Frontline Chemo IO Therapy in SCLC

August 14th 2023

Laurent Greiller, MD, and Christian Grohé, MD, consider real-world data and adverse events observed with frontline chemoimmunotherapy in small cell lung cancer.

Early Efficacy of BL-B01D1 in a Phase 1 Study Reflects Potential for ADCs in Lung Cancer and Beyond

August 11th 2023

Helena A. Yu, MD, discusses the investigation of BL-B01D1 in patients with advanced solid tumors, the potential significance of this research for those with EGFR-mutant and wild-type disease, and the expanding body of evidence supporting continued antibody-drug conjugate development in non–small cell lung cancer.